Skip to main content
. Author manuscript; available in PMC: 2013 Apr 7.
Published in final edited form as: Arch Gen Psychiatry. 2011 Aug 1;68(12):1195–1206. doi: 10.1001/archgenpsychiatry.2011.83

Table 1.

Key baseline demographic, clinical, and smoking information.

Varenicline Group Placebo Group Statistics
ALL NSK SK ALL NSK SK F or
X2 		p
values
Clinical
Information		 N 32 13 19 32 11 21 0.27 0.61
Male:Female 20:12 7:6 13:6 22:10 8:3 14:7 0.28 0.60
Age 44.03
(1.82)a 		45.69
(2.64)		 43.00
(2.52)		 41.57
(193)		 42.09
(3.15)		 41.48
(2.49)		 0.86 0.36
BPRS Baseline Total 34.13
(1.44)		 31.08
(1.99)		 36.21
(1.90)		 34.69
(1.52)		 34.00
(2.49)		 35.05
(1.96)		 0.07 0.79
HAM-D Baseline Total 5.16
(0.70)		 5.31
(1.12)		 5.05
(0.93)		 6.06
(0.82)		 6.64
(0.98)		 5.76
(1.15)		 0.70 0.40
Smoking
Information		 FTND 5.05
(0.60)		 4.90
(0.46)		 0.04 0.84
Pack-year 24.62
(5.52)		 22.50
(6.13)		 0.06 0.80
Age start smoking 17.21
(1.32)		 16.52
(1.72)		 0.10 0.76
Age start regular smoking 19.37
(1.36)		 19.19
(1.80)		 0.01 0.94
CPD Baseline 19.21
(3.15)		 17.19
(2.84)		 0.23 0.64
a

Mean (standard error)